Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy for pediatirc relapsed and Refractory Acute lymphoblastic leukemia followed by TCRαβ-depleted haplo-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

HXHaoran Xiao

Discussion

Loading...

Member takes

Overview

Observational analysis reveals CAR-T therapy with haplo-Donor lymphocyte infusion improves outcomes in pediatric R/R-ALL.

Key Points

  • Favorable outcomes arise from haplo-Donor lymphocyte infusion following CAR-T therapy in pediatric patients.
  • The overall survival and leukemia-free survival rates reached 90.1% and 83.2%, respectively, after haplo-HSCT.
  • Assessment using TCRαβ-depleted haplo-HSCT shows effective engraftment with minimal acute and chronic GVHD incidence.
  • Supports the potential of haplo-DLI in enhancing transplant efficacy and increasing survival in pediatric leukemia patients.

Cite This Study

Haoran Xiao (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d485https://doi.org/10.1182/blood-2025-2529
View Full Paper
Ask AI
Bookmark
Share